DOR BioPharma, Inc. is a pharmaceutical company specializing in the oral and mucosal delivery of drugs and vaccines.

 Through our newly-formed Biodefense Division, we are developing vaccines for a series of biological agents that currently pose a significant bioterrorism or biowarfare threat. Our vaccines are based on the MicroVax™ technology, a proprietary encapsulation system that protects sensitive vaccine materials and permits their efficient delivery to the body’s immune system.

Additionally, our Biotherapeutics Division is developing oral and mucosal drugs which are traditionally delivered in non-oral formats. We anticipate our oral products will enhance patient quality of life, patient compliance to therapy and potentially reduce healthcare costs. The Company’s lead product, orBec™ (oral beclomethasone dipropionate), is currently in a pivotal phase III clinical trial for the treatment of intestinal graft-vs.-host disease and the Company is currently testing orBec™’s usefulness in treating a large percentage of persons diagnosed with irritable bowel syndrome (IBS), a disease that affects approximately 35 million persons in the U.S. alone. 


Ralph M. Ellison
President & Chief Executive Officer


Geoff Green
Vice President of Clinical Operations


Robert N. Brey, PhD
Vice President, Research and Development


William Milling
Controller/Treasurer/Corporate Secretary


General Alexander M. Haig, Jr.
Chairman of the Board


Steve Kanzer, JD, CPA
Vice Chairman of the Board
Accredited Ventures Incorporated


Larry J. Kessel, MD,
Private Practice in Internal and Geriatric Medicine


Arthur Asher Kornbluth, MD
Associate Clinical Professor of Medicine at Mount Sinai Medical Center and School of Medicine, New York City


Evan Myrianthopoulos
President and Founder of CVL Advisors, LLC


Paul Rubin, MD
Executive Vice President, Drug Development, Sepracor, Inc.


Peter Salomon, MD FACG
Gastroenterology Associates of South Florida






Transfer Agent and Registrar: 


American Stock Transfer & Trust Company
40 Wall Street
New York, NY 10005
(800) 937-5449
.
Attorneys: 

Katten Muchin Zavis Rosenman
525 West Monroe Street
Chicago, IL 60661.
 
Accountants: 

Ernst & Young LLP
111 E. Kilbourn Avenue
Suite 1300
Milwaukee, WI 53202